Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
An announcement from Neurotech International Ltd. ( (AU:NTI) ) is now available.
Neurotech International Ltd has entered into a development agreement with RH Farma Dooel Skopje, a subsidiary of European Cannabis Company, to create a pharmaceutical-grade broad-spectrum cannabinoid drug product for pediatric neurodevelopmental disorders. This collaboration is intended to expand Neurotech’s market reach and enhance product quality using ECC’s expertise in cannabis-based product development and manufacturing. The agreement aligns with Neurotech’s strategic goal to meet global demand for high-quality cannabis-derived pharmaceuticals and further reinforces the company’s position in the industry.
More about Neurotech International Ltd.
Neurotech International Limited is a clinical-stage biopharmaceutical development company focused primarily on pediatric neurological disorders. The company offers a broad-spectrum oral cannabinoid drug therapy, NTI164, and has conducted various clinical trials in Autism Spectrum Disorder (ASD) and other pediatric neuropsychiatric disorders. Neurotech is committed to innovation and regulatory compliance, with ongoing efforts in clinical trials and collaborations with medical institutions.
YTD Price Performance: -26.67%
Average Trading Volume: 655,913
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$45.85M
See more data about NTI stock on TipRanks’ Stock Analysis page.
